Yahoo · Oct 2, 2026
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Boston Scientific (BSX) closed at $42.6, marking a -1.46% move from the previous day.
NYSE · BSX
Boston Scientific Corporation
Healthcare · Medical - Devices
$42.04
Up+$0.69 (+1.64%)
Updated Oct 9, 2026, 8:54 PM
SID Score
4.9/10
Composite research score
Smart Money
63/100
Neutral
- Market cap
- 135.98B
- P/E ratio
- 48.75
- Dividend yield
- 0.00%
- 52-week range
- $41.39 – $100.90
- Volume
- 22.88M
- Avg. volume
- 9.87M
Price performance · BSX
BSX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
BSX closed at $42.04 after 21 trading sessions, down 2.46% for the selected period.
- Last close
- $42.04
- Period change
- -2.46%
- Period low
- $41.58
- Period high
- $45.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $41.50 | $42.27 | $41.385 | $42.04 | 22.88M |
| Oct 7, 2026 | $42.19 | $42.515 | $41.50 | $41.58 | 15.89M |
| Oct 6, 2026 | $42.47 | $42.75 | $41.995 | $42.19 | 12.55M |
| Oct 5, 2026 | $42.53 | $43.30 | $42.285 | $42.40 | 13.74M |
| Oct 2, 2026 | $43.315 | $43.44 | $41.9397 | $42.60 | 18.31M |
| Oct 1, 2026 | $43.51 | $43.96 | $42.95 | $43.23 | 17.94M |
| Sep 30, 2026 | $43.74 | $43.97 | $43.30 | $43.65 | 17.97M |
| Sep 29, 2026 | $44.145 | $44.30 | $43.22 | $43.88 | 14.61M |
| Sep 28, 2026 | $43.91 | $44.15 | $43.165 | $44.11 | 21.78M |
| Sep 25, 2026 | $44.68 | $44.84 | $43.325 | $43.92 | 15.21M |
| Sep 24, 2026 | $44.65 | $45.16 | $44.46 | $44.68 | 17.3M |
| Sep 23, 2026 | $45.00 | $45.74 | $43.985 | $44.62 | 18.57M |
| Sep 22, 2026 | $44.70 | $45.08 | $44.04 | $44.92 | 21.08M |
| Sep 21, 2026 | $42.98 | $43.81 | $42.72 | $43.72 | 25M |
| Sep 18, 2026 | $43.08 | $43.90 | $43.05 | $43.34 | 29.28M |
| Sep 17, 2026 | $43.465 | $43.66 | $42.95 | $43.55 | 32.57M |
| Sep 16, 2026 | $43.85 | $44.665 | $43.6501 | $43.91 | 28.48M |
| Sep 15, 2026 | $44.32 | $44.9889 | $43.68 | $43.87 | 16.02M |
| Sep 14, 2026 | $44.00 | $45.15 | $43.85 | $45.05 | 20.52M |
| Sep 11, 2026 | $43.19 | $43.55 | $42.795 | $42.98 | 26.99M |
| Sep 10, 2026 | $44.13 | $44.42 | $42.78 | $43.10 | 22.69M |
Latest BSX news
The latest Smart Investors Daily articles mentioning BSX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BSX research
Overview
Company profile and research snapshot.
Company profile
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $127.00
- Implied upside
- —
- Analysts
- 24
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Oct 5, 2026 | Citigroup | Neutral | — |
| Sep 24, 2026 | Wells Fargo | Equal-Weight | — |
| Sep 21, 2026 | Oppenheimer | Outperform | — |
| Sep 17, 2026 | Citigroup | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Cyted Health appoints Thomas West as Board Chair and Robert Epstein as Non-Executive Director to drive US growth
Cyted Health, a leading gastrointestinal molecular diagnostics company, today announced the appointment of Thomas West as Chair of its Board of Directors and Non-Executive Director, and the appointment of Robert Epstein as a Non-Executive Director, to support the company's continued commercial growth across the US and UK.
Yahoo · Sep 28, 2026
Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem?
Wells Fargo has put a number on the damage Boston Scientific Corporation’s (NYSE:BSX) August cybersecurity incident could do to its third-quarter results, which comes up to roughly $300 million in sales and about $0.13 per share in earnings. Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Boston Scientific to $48 from $50 […]
Benzinga · Sep 28, 2026
FDA Flags Boston Scientific Catheter Recall
Boston Scientific recalls Imager II Angiographic Catheters over tip detachment defect. Learn about patient risks & FDA safety updates.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
